Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, December 2001, p. 3574-3579, Vol. 45, No. 12
Department of Microbiology and Molecular
Genetics,1 Center for the Study of
Emerging and Re-emerging Pathogens,3 and
Division of Infectious Diseases,2
University of Texas Medical School, Houston, Texas 77030
Received 28 February 2001/Returned for modification 9 July
2001/Accepted 7 September 2001
We hypothesized that multidrug resistance efflux pumps (MDRs) may
be contributing to the drug resistance of enterococci. We recently
identified potential MDR-encoding genes in the Enterococcus faecalis V583 genome. Among the putative MDRs, we found a
gene that encodes a NorA homolog and have characterized this
enterococcal MDR in the present study. A mutant from which the
enterococcal NorA homolog has been deleted has reduced resistance to
several NorA substrates. Complementation of the deletion mutant with
the wild-type gene verified the involvement of this enterococcal gene in resistance to ethidium bromide (EtBr) and norfloxacin. Known MDR
inhibitors (reserpine, lansoprazole, and verapamil) inhibit the efflux
of EtBr and norfloxacin in wild-type strain OG1RF. A fluorescence assay
with EtBr allowed us to quantitate the efflux capability of the
enterococcal NorA pump. On the basis of these results, we have named
this enterococcal gene emeA (enterococcal multidrug
resistance efflux).
Many enterococcal isolates
are resistant to the majority of antimicrobial agents that are in
clinical use. This causes therapeutic problems, especially for patients
with serious, multidrug-resistant enterococcal infections. Enterococci
are equipped with a variety of antibiotic resistance genes, some of
which are inherent and some of which are acquired. The intrinsic
resistance of enterococci to certain antibiotics may be partially due
to genes that encode multidrug resistance efflux pumps (MDRs).
MDRs are found in a variety of organisms ranging from bacteria to
humans, suggesting their universal importance. Although the primary
functions and mechanisms of action for most MDRs remain unclear, these
proteins are known to actively transport toxic compounds out of the
cell. Antibiotic-specific efflux pumps ([e.g, Tet(K) and CmlA)] are
often encoded on transmissible plasmids and transposons in bacteria.
However, most genes for MDRs are encoded on the bacterial chromosome
(6).
In a number of other bacteria, MDRs have also been implicated as
important contributors to multidrug resistance (3, 4, 5,
7). Because enterococci are intrinsically resistant to a variety
of antibiotics, it seems reasonable to assume that MDRs could be
contributing to the drug resistance. However, there has been only one
study on MDRs in enterococci prior to the present study. Enterococci
were shown to extrude chloramphenicol, tetracycline, and norfloxacin;
but the efflux pump(s) responsible for extruding these drugs was not
identified (9). The need to identify drug efflux pumps, to
find suitable drug targets, and to understand drug resistance has led
to our investigation of MDRs in enterococci. Previously, we used a
genomics approach to identify 34 potential enterococcal MDR-encoding
genes (2). We have now characterized an enterococcal MDR,
EmeA, which was identified because of its sequence homology to
Staphylococcus aureus NorA, and have demonstrated that EmeA
is involved in the resistance of enterococci to various unrelated
compounds. Known MDR inhibitors were also effective at inhibiting drug
efflux in enterococci. Our analysis demonstrates that EmeA is an MDR
that belongs to the major facilitator superfamily (MFS).
Bacterial strains, plasmids, and culture conditions.
The
bacterial strains and plasmids used in the study are listed in Table
1. All Escherichia coli
strains were grown by using standard conditions (15). All
Enterococcus faecalis strains were grown with aeration at
37°C in brain heart infusion (BHI), Todd-Hewitt (TH; Difco
Laboratories, Detroit, Mich.), or Mueller-Hinton cation-adjusted (MH
II; Becton Dickinson) broth or agar supplemented with appropriate
antibiotics. The antibiotics used for E. coli included
ampicillin at 100 µg/ml, kanamycin (KAN) at 25 µg/ml, chloramphenicol at 25 µg/ml, and erythromycin (ERY) at 300 µg/ml. The antibiotics used for E. faecalis included KAN at 1 to 2 mg/ml and ERY at 10 µg/ml.
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.12.3574-3579.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Characterization of emeA, a
norA Homolog and Multidrug Resistance Efflux Pump, in
Enterococcus faecalis
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results and Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results and Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results and Discussion
References
TABLE 1.
Strains and plasmids used in the
studya
Chemicals and antibiotics. Antibiotics, carbonyl cyanide m-chlorophenylhydrazone (CCCP), ethidium bromide (EtBr), verapamil, lansoprazole, and reserpine were purchased from Sigma-Aldrich Chemical Co. (St. Louis, Mo.). CCCP was dissolved in dimethyl sulfoxide (100 mM); verapamil was dissolved in distilled H2O (dH2O; 10 mg/ml); reserpine was dissolved in CHCl3 (10 mg/ml) and then diluted in MH II broth, as needed; lansoprazole (125 mg) was first dissolved in 5 ml of methanol and was then diluted to 5 mg/ml in dH2O; and norfloxacin was suspended in dH2O (one-half of the total volume needed), and 100 mM NaOH was added (in 100-µl aliquots) until the solution became clear and then the solution was diluted to the desired concentration with dH2O.
MIC testing. MIC testing was performed with MH II medium in microtiter plates and on agar dilution plates by the protocols provided by NCCLS (11). The compounds tested were diluted and tested at several different concentrations in order to determine more precise MICs. MICs were recorded as the lowest concentration of antibiotic that totally inhibited growth after 20 h of incubation at 35°C. The compounds tested included EtBr, norfloxacin, verapamil, lansoprazole, and reserpine. Each test was performed at least in triplicate. As a control, E. faecalis ATCC 29212 was included in tests for MICs. Strains tested on E-test strips (PDM Epsilometer test; AB Biodisk North America, Inc., Piscataway, N.J.) were suspended in 0.8% saline to a 0.5 McFarland standard (~107 CFU/ml); the bacteria were then swabbed onto Mueller-Hinton agar plates and allowed to dry for about 10 min. After the plates were dry, the E-test strips were placed in the middle of the plate with the labeled side up. The plates were incubated overnight at 37°C. The MICs were determined as the lowest concentration of drug that totally inhibited growth.
EtBr efflux assay. Cultures of bacteria were grown overnight in BHI broth at 37°C. The cells were then pelleted and washed two times with 20 mM HEPES buffer (pH 7.0). The cells were resuspended in HEPES buffer to 30 Klett units (~2 × 108 CFU/ml). The cells were then loaded with EtBr by shaking of the cells at 37°C and the addition of CCCP (final concentration, 40 µM) to dissipate the membrane potential and EtBr (final concentration, 2.5 µM). The cells were incubated for 1 h. The cells were then washed three times with HEPES buffer containing EtBr (2.5 µM) and were resuspended in the same buffer to 15 Klett units (~2 × 107 CFU/ml). The cells were stored on ice until initiation of efflux. Efflux was initiated by the addition of 80 µl of TH broth to 3 ml of the cell suspension. In some cases, efflux pump inhibitors (reserpine at 20 µg/ml, verapamil at 100 µg/ml, lansoprazole at 100 µg/ml) were added before the addition of TH broth. The concentrations of the efflux pump inhibitors were chosen on the basis of previous research (1). Fluorescence was measured with a spectrophotomer (Photon Technology International, Lawrenceville, N.J.) every 30 s for 30 to 35 min with an excitation wavelength of 500 nm and an emission wavelength of 590 nm. All measurements were performed in triplicate.
DNA preparations and transformation. DNA preparation, purification, restriction digestion, agarose gel electrophoresis, and ligation were performed by standard methods or following the manufacturer's instructions (15). E. coli transformations and cloning and transformations with the TA and TOPO cloning vectors were performed by the protocol provided by Invitrogen (Carlsbad, Calif.). Electroporation of E. faecalis was performed as described previously (15).
DNA sequencing and sequence analysis. Sequencing reactions were performed by the Taq dye-deoxy terminator method with a 377 DNA sequencing system (PE Applied Biosystems, Foster City, Calif.). Transmembrane sequences were identified by using TMHMM or SOSUI at ExPASy. Also, SignalP was used to identify signal sequences. BLAST program searches were performed by using the National Center for Biotechnology Information (NCBI) website, the Baylor College of Medicine Search Launcher website, and GCG (Genetics Computer Group, Madison, Wis.) programs. The ORF Finder at the NCBI website was used to identify open reading frames. Amino acid sequences were obtained by using Entrez at the NCBI website. Multiple sequence alignment was performed with the ClustalW (version 1.8) program at the Baylor College of Medicine Search Launcher website.
PCR and protocols.
The sequences of the primers used in the
PCRs are shown in Table 2. PCR reagents
and enzymes were purchased from Perkin-Elmer. Standard and colony PCRs
were performed as described previously (15). Long-range
PCR was performed with a GeneAmp XL PCR kit according to the
manufacturer's recommendations.
|
Crossover PCR. Crossover PCR was performed as described previously (8). Primers 511 and 502 were used to amplify the left flanking region (~534 bp) of emeA. Primers 499 and 500 were used to amplify the right flanking region (~1,073 bp). The flanking regions were amplified from cosmid template BO1C6(2), which contains emeA on an ~40-kb insert of E. faecalis strain OG1RF chromosomal DNA (Table 1). The crossover PCR product of the flanking regions (1.607 kb) was gel purified and extracted and was then ligated into the TOPO-TA cloning vector (Invitrogen) and transformed into E. coli TOP10F' by the TOPO cloning protocol. The correct transformant strain, GW4475, which contained the construct pGW4475, was verified by restriction enzyme analysis and DNA sequencing.
Insertional mutagenesis. A disruption mutant of emeA was obtained by standard methods (15). An internal fragment of emeA (~603 bp) was amplified with primers 455 and 456. The PCR product was cloned between the BamHI and EcoRI sites of the pTEX4577 vector. This construct (pGW4427) was electroporated into E. faecalis OG1RF competent cells.
Deletion of emeA from chromosome of OG1RF and
complementation.
The 1.6-kb insert of the flanking regions was
released from pGW4475 with EcoRI and was ligated into the
EcoRI site of pTEX4577 (resulting in plasmid pGW4476),
transformed into E. coli DH5
cells, and plated onto
Luria-Bertani agar containing KAN (25 µg/ml), isopropyl-
-D-thiogalactopyranoside, and
5-bromo-4-chloro-3-indolyl-
-D-galactopyranoside. Plasmid
DNA from transformant colonies was verified by digestion with
EcoRI, agarose gel electrophoresis, and DNA sequencing. The pGW4476 construct was then electroporated into OG1RF competent cells,
and the cells were plated onto TH agar with KAN (2 mg/ml). After
overnight incubation, several colonies were obtained and restreaked.
Integration of pGW4476 into the chromosome of OG1RF was verified by
colony PCR with primers 513 and 516. Transformant GW4477
(OG1RF::pGW4476) was used to obtain the deletion mutant. First, an overnight culture was diluted 100-fold and was grown in BHI
broth at 37°C for 90 min. Aliquots were plated onto TH agar plates,
and colonies were then replica plated onto TH agar plates with and
without KAN (2 mg/ml). Colonies that were no longer resistant to KAN
were then tested for possible deletion of emeA by colony PCR
with primers 500 and 511.
emeA, primers 500 and 511 were used to amplify the emeA open reading frame (ORF) from
strains V583, OG1RF, and the OG1RF
emeA mutant (only
flanking regions of emeA were amplified). The PCR products
were cloned separately into the EcoRI site of the pAT18
enterococcal shuttle vector (Table 1). The pAT18 constructs were then
transformed into E. coli cells, plasmid DNA was extracted,
and the constructs were confirmed by sequencing and restriction enzyme
digestion. Next, the pAT18 constructs were electroporated into
OG1RF
emeA competent cells, and transformants were
selected on TH agar plates containing ERY (10 µg/ml). After overnight
incubation, complemented transformants were restreaked onto selective
plates. The presence of the pAT18 constructs was verified by colony PCR
with primers M13F and M13R (Table 2).
| |
RESULTS AND DISCUSSION |
|---|
|
|
|---|
Characterization of emeA. emeA was identified by searching the E. faecalis V583 database with the sequence of the S. aureus NorA protein (accession number M80252). Once the ORF was identified, the enterococcal protein sequence was used to search the nonredundant protein database (NCBI website). EmeA shows 32% identity to NorA from S. aureus and 39 to 40% identities to Bmr2 and Bmr1 efflux pumps, respectively, from Bacillus subtilis. EmeA consists of 380 amino acids and has 12 predicted transmembrane regions and a predicted signal peptide. These characteristics are similar to those of other MFS MDRs (13).
Figure 1 shows the alignments between the sequences of the EmeA, Bmr2, Bmr1, and NorA proteins. The translocase consensus sequence (GXXXDR/KXGRR/K) and the drug extrusion (DE) consensus sequence (GXhyhyGPXXGG [where hy represents some hydrophobic residue and X represents any residue]), which are found in most MFS MDRs, are conserved in all four sequences (13). MDRs and specific efflux pumps from the same families share the same DE consensus sequence. Therefore, this sequence apparently codes for a domain that determines the direction of transport of a ligand, which demonstrates the similarity between MDRs and conventional translocases (7). The sequences of MDRs do not point to any particular multidrug consensus sequence.
|
Mutagenesis of emeA in E. faecalis and MIC testing. In order to determine if the emeA ORF encodes a product involved in resistance to toxic compounds, we initially used insertional mutagenesis to inactivate the gene. Following electroporation of strain OG1RF with pGW4427, 14 KAN-resistant colonies were obtained and their structure was verified by long-range colony PCR with primers 479 and 463. All 14 colonies produced 9.0-kb products, indicating that integration of pGW4427 into the chromosome of OG1RF had occurred. Therefore, the enterococcal emeA had been disrupted. Southern hybridization also confirmed the integration (data not shown).
The MICs for wild-type strain OG1RF and the disruption mutant were determined in triplicate with E-test strips. The mutant strain was approximately twofold more sensitive than the wild type to ciprofloxacin and norfloxacin (data not shown). These results suggested that emeA or a downstream gene is involved in resistance to toxic compounds.Deletion of emeA from OG1RF chromosome, complementation, and susceptibility testing of resulting strains. In order to eliminate the effects of truncated products or the possibility of polar effects on other genes, we sought to delete the gene from the chromosome. Colonies obtained through screening of GW4477 for the loss of KAN resistance were tested for deletion of emeA by PCR. Colony PCR yielded a 2.5-kb product for OG1RF and a 1.6-kb product for GW4481, suggesting deletion of emeA from the OG1RF chromosome. Sequencing showed that emeA was deleted from base pairs 7 through 1079 in strain GW4481.
The OG1RF
emeA mutant was complemented with the wild-type
emeA from OG1RF(pGW4661) or V583(pGW4575) or the PCR product
from the OG1RF
emeA mutant itself (pGW4662, negative
control); complementation was verified by colony PCR (data not shown).
It was observed that, with primers 500 and 511, the PCR product from
V583 was ~3.2 kb and the products from OG1RF and BO1C6(2) were 2.6 kb. Sequence analysis revealed that strain V583 has an additional 630 bp compared to strain OG1RF directly after the stop codon of
emeA; this region is not homologous to any known genes.
In S. aureus, EtBr and norfloxacin are two substrates of the
NorA efflux pump. Also, reserpine, verapamil, and lansoprazole are
inhibitors of many bacterial MDRs including NorA (1).
Therefore, we tested these compounds with the emeA deletion
mutant, wild-type strain OG1RF, and the complemented strains (Table
3). Strain OG1RF
emeA was
twofold more sensitive to EtBr and norfloxacin than wild-type strain
OG1RF was. Also, the norfloxacin MICs for the strains complemented with
emeA from either V583 or OG1RF were increased eightfold
compared to those for OG1RF
emeA. Reserpine (a competitive
pump blocker), verapamil (a calcium channel blocker), and lansoprazole
(a H+ and K+ ATPase pump inhibitor) decreased
the level of resistance of OG1RF to norfloxacin twofold. Resistance to
EtBr was affected only slightly by reserpine, but the level of
resistance was decreased twofold in the presence of lansoprazole or
verapamil. For the complemented strains, there was also a twofold
decrease in the norfloxacin MIC in the presence of reserpine and
lansoprazole; verapamil decreased the EtBr MIC twofold, and
lansoprazole decreased the EtBr MIC fourfold. The MICs of the pump
inhibitors were all above the concentrations used in this assay.
Benzalkonium chloride and sodium dodecyl sulfate were also tested, but
they showed no effect on growth even at very high concentrations.
|
emeA has also been shown to be twofold more
sensitive to acriflavine, ciprofloxacin, clindamycin, erythromycin, and novobiocin (2 [in reference 2,
emeA was referred to as
norA]). These
results verify that emeA in E. faecalis encodes an MDR protein involved in resistance to many unrelated toxic compounds
and that EmeA is affected by several MDR inhibitors.
EmeA seems to have a modest but consistent effect on the susceptibility
of E. faecalis to diverse compounds such as norfloxacin and
EtBr. The reason for this modest effect could be that there are other
pumps and/or mechanisms that confer resistance to these MDR substrates
in the absence of EmeA. Also, it is possible that high-level resistance
to many toxic compounds may depend on the combined effects of many
resistance mechanisms, in which case, the elimination of one mechanism
would not totally abolish resistance.
EtBr efflux assay.
EtBr is highly fluorescent when it is bound
to DNA inside the cell. When the EtBr is effluxed from the cell by way
of an efflux pump, the fluorescence will decrease and this can be
measured with a fluorescence spectrophotometer. The fluorescence of
EtBr was used to measure the efflux of the compound from bacterial cells. The bacterial cells were starved and loaded with EtBr after dissipation of the membrane potential with the protonophore CCCP. Without an energy source the MDRs cannot function; therefore, the EtBr
cannot be effluxed and the cells become loaded. After the cells were
loaded, they were washed to remove the CCCP and were resuspended in
buffer containing EtBr. Efflux of EtBr was initiated by the addition of
a carbon source that allows reconstitution of the membrane potential.
Figure 2A shows that in the presence of
TH broth, wild-type strain OG1RF was able to efflux EtBr. However, without TH broth or the EmeA MDR, EtBr was not pumped out of the bacterial cells. After 35 min there was a 30% difference in
fluorescence between wild-type OG1RF (with TH broth) and
OG1RF
emeA (with TH broth). No decrease in fluorescence
was seen in the mutant or the wild type suspended in buffer only. These
results indicate that EmeA is an energy-dependent MDR.
|
| |
ACKNOWLEDGMENTS |
|---|
We thank John Putkey for advice and assistance with the fluorescence assays and Deb Davis, Abbie White, and Bruce Rogers (Phytera) for collaboration.
The genomic sequence of E. faecalis V583 was provided by The Institute for Genome Research in accordance with a license agreement. This work was supported in part by a grant from Phytera and in part by USPHS grant AI33516 to Barbara E. Murray from DMID of NIH.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Human Genome Sequencing Center, Baylor College of Medicine, One Baylor Plaza, Alkek N1519, Houston, TX 77030. Phone: (713) 798-6539. Fax: (713) 798-5741. E-mail: gwstock{at}bcm.tmc.edu.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Aeschlimann, J. R.,
L. D. Dresser,
G. W. Kaatz, and M. J. Rybak.
1999.
Effects of NorA inhibitors on in vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of Staphylococcus aureus.
Antimicrob. Agents Chemother.
43:335-340 |
| 2. | Davis, D. V., J. B. McAlpine, C. J. Pazoles, M. K. Talbot, E. A. Alder, A. C. White, B. M. Jonas, B. E. Murray, G. M. Weinstock, and B. L. Rogers. 2001. Enterococcus faecalis multi-drug resistance transporters: application for antibiotic discovery. J. Mol. Microbiol. Biotechnol. 3:179-184[CrossRef][Medline].. |
| 3. |
Hsieh, P.-C.,
S. A. Siegel,
B. Rogers,
D. Davis, and K. Lewis.
1998.
Bacteria lacking a multidrug pump: a sensitive tool for drug discovery.
Proc. Natl. Acad. Sci. USA
95:6602-6606 |
| 4. | Jacoby, G. A. 1996. Antimicrobial-resistant pathogens in the 1990s. Annu. Rev. Med. 47:169-179[CrossRef][Medline]. |
| 5. |
Kaatz, G. W.,
S. M. Seo, and C. A. Ruble.
1993.
Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus.
Antimicrob. Agents Chemother.
37:1086-1094 |
| 6. |
Lee, A.,
M. Weimin,
M. S. Warren,
A. Mistry,
K. Hoshino,
R. Okumura,
H. Ishida, and O. Lomovskaya.
2000.
Interplay between efflux pumps may provide either additive or multiplicative effects on drug resistance.
J. Bacteriol.
182:3142-3150 |
| 7. | Lewis, K. 1994. Multidrug resistance pumps in bacteria: variations on a theme. Trends Biochem. Sci. 19:119-123[CrossRef][Medline]. |
| 8. |
Link, A. J.,
D. Phillips, and G. Church.
1997.
Methods for generating precise deletions and insertions in the genome of wild-type Escherichia coli: application to open reading frame characterization.
J. Bacteriol.
179:6228-6237 |
| 9. | Lynch, C., P. Courvalin, and H. Nikaido. 1997. Active efflux of antimicrobial agents in wild-type strains of enterococci. Antimicrob. Agents Chemother. 41:869-871[Abstract]. |
| 10. |
Murray, B. E.,
K. V. Singh,
P. R. Ross,
J. D. Heath,
G. M. Dunny, and G. M. Weinstock.
1993.
Generation of restriction map of Enterococcus faecalis OG1 and investigation of growth requirements and regions encoding biosynthetic function.
J. Bacteriol.
175:5216-5223 |
| 11. | National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa. |
| 12. |
Nielsen, H.,
J. Engelbrecht,
S. Brunak, and G. von Heijne.
1997.
Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites.
Protein Eng.
10:1-6 |
| 13. |
Ohki, R., and M. Murata.
1997.
bmr3, a third multidrug transporter gene of Bacillus subtilis.
J. Bacteriol.
179:1423-1427 |
| 14. |
Sahm, D. F.,
J. Kissinger,
M. S. Gilmore,
P. R. Murray,
R. Mulder,
J. Solliday, and B. Clarke.
1989.
In vitro susceptibility studies of vancomycin-resistant Enterococcus faecalis.
Antimicrob. Agents Chemother.
33:1588-1591 |
| 15. | Singh, K. V., X. Qin, and G. M. Weinstock. 1998. Generation and testing of mutants of Enterococcus faecalis in a mouse peritonitis model. J. Infect. Dis. 178:1416-1420[CrossRef][Medline]. |
| 16. |
Trieu-Cout, P.,
C. Carlier,
C. Poyart-Salmeron, and P. Courvalin.
1991.
Shuttle vectors containing a multiple cloning site and a lacZ gene for conjugal transfer of DNA from Escherichia coli to gram-positive bacteria.
Gene
102:99-104[CrossRef][Medline].
|
| 17. |
Xu, Y.,
K. V. Singh,
X. Qin,
B. E. Murray, and G. M. Weinstock.
2000.
Analysis of a gene cluster of Enterococcus faecalis involved in polysaccharide biosynthesis.
Infect. Immun.
68:815-823 |
| 18. | Xu, Y., L. Jiang, B. E. Murray, and G. M. Weinstock. 1997. Enterococcus faecalis antigens in human infections. Infect. Immun. 65:4207-4215[Abstract]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |